U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H26O6
Molecular Weight 386.4382
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOFOGLIFLOZIN ANHYDROUS

SMILES

CCC1=CC=C(CC2=CC=C3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=C2)C=C1

InChI

InChIKey=VWVKUNOPTJGDOB-BDHVOXNPSA-N
InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H26O6
Molecular Weight 386.4382
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Tofogliflozin is a SGLT2 selective inhibitor which was developed by Chugai Pharmaceutical for the treatment of Type 2 Diabetes Mellitus. The drug was approved in Japan in 2013 and it is being marketed under the names Apleway and Debereza.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.9 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DEBERZA

Approved Use

The treatment of type 2 diabetes mellitus.

Launch Date

2012
PubMed

PubMed

TitleDatePubMed
Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
2012 Jun
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
2012 Sep 13
In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
2013 Apr
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
2013 Feb 15
Patents

Sample Use Guides

In general, for adults, take 20 mg of tofogliflozin once a day, before or after breakfast.
Route of Administration: Oral
Primary cultured proximal tubular epithelial cells from human normal kidney were treated with or without 3 nM or 30 nM tofogliflozin and with or without 22.8 mM glucose. Tofogliflozin dose-dependently suppressed glucose entry into tubular cells.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:47:53 GMT 2023
Edited
by admin
on Fri Dec 15 19:47:53 GMT 2023
Record UNII
554245W62T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOFOGLIFLOZIN ANHYDROUS
Common Name English
CSG452
Code English
(1S,3'R,4'S,5'S,6'R)-6-((4-ETHYLPHENYL)METHYL)-6'-(HYDROXYMETHYL)-3',4',5',6'-TETRAHYDRO-3H-SPIRO(2-BENZOFURAN-1,2'-PYRAN)-3',4',5'-TRIOL
Systematic Name English
CSG-452
Code English
RO-4998452
Code English
RO4998452
Code English
TOFOGLIFLOZIN [MI]
Common Name English
SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL,6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)-,(1S,3'R,4'S,5'S,6'R)-
Common Name English
tofogliflozin [INN]
Common Name English
R-7201
Code English
Tofogliflozin [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98083
Created by admin on Fri Dec 15 19:47:54 GMT 2023 , Edited by admin on Fri Dec 15 19:47:54 GMT 2023
Code System Code Type Description
FDA UNII
554245W62T
Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
PRIMARY
CAS
903565-83-3
Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
PRIMARY
NCI_THESAURUS
C152676
Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
PRIMARY
EVMPD
SUB177215
Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
PRIMARY
PUBCHEM
46908929
Created by admin on Fri Dec 15 19:47:54 GMT 2023 , Edited by admin on Fri Dec 15 19:47:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID90238097
Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
PRIMARY
MERCK INDEX
m11867
Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
PRIMARY
SMS_ID
100000163089
Created by admin on Fri Dec 15 19:47:54 GMT 2023 , Edited by admin on Fri Dec 15 19:47:54 GMT 2023
PRIMARY
INN
9275
Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE INACTIVE -> PARENT
20.4 EXCRETED IN FECES
MAJOR
FECAL
METABOLITE INACTIVE -> PARENT
76% OF TOTAL DOSE EXCRETED IN URINE;
MAJOR
URINE
METABOLITE -> PARENT
MINOR
FECAL; PLASMA; URINE
METABOLITE -> PARENT
PERCENT OF TOTAL DOSE
URINE
METABOLITE INACTIVE -> PARENT
MAJOR
FECAL; PLASMA; URINE
METABOLITE -> PARENT
PERCENT OF AUC
PLASMA
METABOLITE INACTIVE -> PARENT
TAKEN FROM AUC
MAJOR
PLASMA
METABOLITE -> PARENT
PERCENT OF TOTAL DOSE
FECAL
Related Record Type Details
ACTIVE MOIETY